Rhythm Pharmaceuticals Inc (RYTM)

$103.27 +1.59 (1.56%)
Market Cap 6.86B
Revenue (ttm) 130.13M
Net Income (ttm) -260.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -200.26%
Debt to Equity Ratio 0.00
Volume 711,700
Avg Vol 744,962
Day's Range N/A - N/A
Shares Out 66.42M
Stochastic %K 86%
Beta 2.38
Analysts Strong Sell
Price Target $111.93

Company Profile

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid r...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 264 4280
Fax: 857 264 4299
Address:
222 Berkeley Street, 12th Floor, Boston, United States
abcdzepeda
abcdzepeda Aug. 22 at 3:06 PM
$RYTM Timing is everything, after Jerome Powell’s speech today everything is pointing towards a rate cut in September. This is going to set us up nicely, because we have a conference call on September 24 for investors to hear the game plan for the launch of HO in the US and in EU. When the rate cuts begin, our economy is going to boom. And investors will be eager to invest in a company like rhythm who is also booming. I don’t know if we will be bought out., Because it would require a huge amount of money to buy us out. Bottom line is that we are in for a very interesting ride! Have an awesome weekend rhythmites!
0 · Reply
TeeMan123
TeeMan123 Aug. 22 at 2:02 PM
$RYTM we being bought out or something!?!?
0 · Reply
KingofStocksAce
KingofStocksAce Aug. 21 at 11:38 PM
$RYTM +3,000% since. It was a gem…
2 · Reply
abcdzepeda
abcdzepeda Aug. 21 at 8:02 PM
$RYTM way to close it out!
0 · Reply
abcdzepeda
abcdzepeda Aug. 21 at 3:58 PM
$RYTM
0 · Reply
TeeMan123
TeeMan123 Aug. 21 at 2:46 PM
$RYTM GIVE US $100!!!!!!!!!!!!!!!!!!!!
1 · Reply
biolover
biolover Aug. 21 at 12:53 PM
$GPCR $RYTM $SLNO $VKTX RYTM drug total rip off $ 400,000-500000 per year for wt loss in syndrome obesity. This is how the health care operates. Obviously supported by many bio hedge funds hoping for BO. I don’t believe this malfunctioning price disparity will last.
1 · Reply
Quantumup
Quantumup Aug. 21 at 12:38 PM
Citizens reiterated $RYTM Market Outperform-$135 and said: We are pleased that the FDA accepted the sNDA and the Priority Review speaks to the unmet need and strength of the setmelanotide submission. LLY $VKTX NVO $GPCR TERN $AARD $SLNO Citizens added:
0 · Reply
wrengler4
wrengler4 Aug. 21 at 11:16 AM
$AGIO $QURE check out the history of Matt Kapusta at QURE and his selling of options in 2021, 2022 and 2023 in the 30’s , much like the antics of goof ball GOFF, here … No investor makes money , due to there inabilities to create value , but the bozos sell each chance they get !! GOFF DOESNT GIVE A FCUK ..it is the MATT KAPUSTA theory : MILK THE SOB as long as you can before they oust you for : poor performance for inside fund shareholders !!! GOFF has brought no value in 3 years this month ! FOUSE NEVER DID !!! she created a NEW HISTORIC LOW $16.95 from $62.10 !!!! ( but she was always a loser from Bunge and discarded from Celgene , but was David Schenkien’s girl,Friday ) The game is the same with these two losers , Kapusta and Goff !!! David Meeker , $RYTM, are you reading this ??? Your RYTM was $3 in 2023, today $98 !!! Guess one knows , WHO is with creating value and WHOM ARE NOT !!!!
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 21 at 9:53 AM
WATCHLIST AUG 21 2025. $RYTM Rhythm Pharmaceuticals Announces The FDA Has Accepted Its Supplemental New Drug Application For Setmelanotide To Treat Acquired Hypothalamic Obesity $MSW Ming Shing Group Enters Into A Bitcoin Purchase Agreement With Winning Mission Group Limited For The Purchase Of 4,250 Bitcoins $BZ Jefferies Maintains Buy on Kanzhun, Raises Price Target to $24 $CNVS Cineverse And ElementalTV Form Strategic Partnership To Enhance Streaming Reach With Advanced Audience Intelligence And Identity Resolution $LTH Life Time Launches Melatonin-Free Sleep Supplement 'LTH Dream' With Triple Magnesium Blend For Restful, Grogginess-Free Sleep
0 · Reply
Latest News on RYTM
Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity

Aug 20, 2025, 4:01 PM EDT - 4 days ago

Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 5:26 PM EDT - 19 days ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2025 Earnings Call Transcript

Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update

Aug 5, 2025, 7:00 AM EDT - 20 days ago

Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

Jul 22, 2025, 4:01 PM EDT - 4 weeks ago

Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

Jul 12, 2025, 6:00 PM EDT - 6 weeks ago

Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025

Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market

Jul 10, 2025, 3:39 PM EDT - 6 weeks ago

Rhythm: Oral Bivamelagon Data Signals Dominance In Hypothalamic Obesity Market

Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock

Jul 10, 2025, 6:21 AM EDT - 6 weeks ago

Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Jul 9, 2025, 4:16 PM EDT - 6 weeks ago

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity

Jul 9, 2025, 8:00 AM EDT - 6 weeks ago

Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity

Jul 8, 2025, 4:01 PM EDT - 6 weeks ago

Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals: Rare Genetic Obesity Pioneer With Excellent Prospects

Jun 30, 2025, 11:00 AM EDT - 7 weeks ago

Rhythm Pharmaceuticals: Rare Genetic Obesity Pioneer With Excellent Prospects

Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025

Jun 25, 2025, 8:00 AM EDT - 2 months ago

Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025

Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program

May 14, 2025, 8:00 AM EDT - 3 months ago

Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program

Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript

May 7, 2025, 3:21 PM EDT - 3 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript

Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

May 7, 2025, 7:00 AM EDT - 3 months ago

Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

May 6, 2025, 8:00 AM EDT - 3 months ago

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

Apr 23, 2025, 8:00 AM EDT - 4 months ago

Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder

Apr 8, 2025, 1:38 PM EDT - 4 months ago

Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder

Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial

Apr 7, 2025, 7:11 AM EDT - 5 months ago

Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial

Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

Apr 7, 2025, 7:00 AM EDT - 5 months ago

Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity

Apr 6, 2025, 12:00 PM EDT - 5 months ago

Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity

Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty

Mar 31, 2025, 2:05 PM EDT - 5 months ago

Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty

XBI ALNY VRTX XENE

Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.

Mar 20, 2025, 4:01 PM EDT - 5 months ago

Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.

Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan

Mar 19, 2025, 4:01 PM EDT - 5 months ago

Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan

Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration

Mar 18, 2025, 7:00 AM EDT - 5 months ago

Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration

Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 1:46 PM EST - 6 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2024 Earnings Call Transcript

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Feb 26, 2025, 7:00 AM EST - 6 months ago

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven

Feb 25, 2025, 11:21 AM EST - 6 months ago

Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025

Feb 13, 2025, 8:00 AM EST - 6 months ago

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

Jan 10, 2025, 7:15 AM EST - 8 months ago

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

Dec 20, 2024, 2:24 PM EST - 8 months ago

Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

Dec 20, 2024, 2:15 PM EST - 8 months ago

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old

Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old

Dec 3, 2024, 6:00 AM EST - 9 months ago

Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

Nov 18, 2024, 7:00 AM EST - 10 months ago

Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

Nov 13, 2024, 6:30 PM EST - 10 months ago

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Nov 13, 2024, 4:01 PM EST - 10 months ago

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 10:45 PM EST - 10 months ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2024 Earnings Call Transcript

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

Nov 5, 2024, 4:01 PM EST - 10 months ago

Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update

Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

Nov 4, 2024, 4:01 PM EST - 10 months ago

Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

Oct 24, 2024, 6:00 AM EDT - 10 months ago

Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome

Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck

Sep 22, 2024, 7:36 AM EDT - 1 year ago

Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck

Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)

Aug 29, 2024, 9:30 AM EDT - 1 year ago

Rhythm: Pivotal Moment Approaching In Hypothalamic Obesity (Rating Upgrade)

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old

Aug 26, 2024, 8:02 AM EDT - 1 year ago

Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old

Three Biotech Stocks to Buy for the "Golden Age of Medicine"

Aug 19, 2024, 1:49 PM EDT - 1 year ago

Three Biotech Stocks to Buy for the "Golden Age of Medicine"

LLY SNY

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 11:22 AM EDT - 1 year ago

Rhythm Pharmaceuticals, Inc. (RYTM) Q2 2024 Earnings Call Transcript

Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update

Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

Jul 31, 2024, 9:10 AM EDT - 1 year ago

Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old

Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

Jul 23, 2024, 7:30 AM EDT - 1 year ago

Rhythm Pharmaceuticals to Report Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency

Jun 28, 2024, 8:00 AM EDT - 1 year ago

Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency

Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024

Jun 3, 2024, 4:02 PM EDT - 1 year ago

Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024

abcdzepeda
abcdzepeda Aug. 22 at 3:06 PM
$RYTM Timing is everything, after Jerome Powell’s speech today everything is pointing towards a rate cut in September. This is going to set us up nicely, because we have a conference call on September 24 for investors to hear the game plan for the launch of HO in the US and in EU. When the rate cuts begin, our economy is going to boom. And investors will be eager to invest in a company like rhythm who is also booming. I don’t know if we will be bought out., Because it would require a huge amount of money to buy us out. Bottom line is that we are in for a very interesting ride! Have an awesome weekend rhythmites!
0 · Reply
TeeMan123
TeeMan123 Aug. 22 at 2:02 PM
$RYTM we being bought out or something!?!?
0 · Reply
KingofStocksAce
KingofStocksAce Aug. 21 at 11:38 PM
$RYTM +3,000% since. It was a gem…
2 · Reply
abcdzepeda
abcdzepeda Aug. 21 at 8:02 PM
$RYTM way to close it out!
0 · Reply
abcdzepeda
abcdzepeda Aug. 21 at 3:58 PM
$RYTM
0 · Reply
TeeMan123
TeeMan123 Aug. 21 at 2:46 PM
$RYTM GIVE US $100!!!!!!!!!!!!!!!!!!!!
1 · Reply
biolover
biolover Aug. 21 at 12:53 PM
$GPCR $RYTM $SLNO $VKTX RYTM drug total rip off $ 400,000-500000 per year for wt loss in syndrome obesity. This is how the health care operates. Obviously supported by many bio hedge funds hoping for BO. I don’t believe this malfunctioning price disparity will last.
1 · Reply
Quantumup
Quantumup Aug. 21 at 12:38 PM
Citizens reiterated $RYTM Market Outperform-$135 and said: We are pleased that the FDA accepted the sNDA and the Priority Review speaks to the unmet need and strength of the setmelanotide submission. LLY $VKTX NVO $GPCR TERN $AARD $SLNO Citizens added:
0 · Reply
wrengler4
wrengler4 Aug. 21 at 11:16 AM
$AGIO $QURE check out the history of Matt Kapusta at QURE and his selling of options in 2021, 2022 and 2023 in the 30’s , much like the antics of goof ball GOFF, here … No investor makes money , due to there inabilities to create value , but the bozos sell each chance they get !! GOFF DOESNT GIVE A FCUK ..it is the MATT KAPUSTA theory : MILK THE SOB as long as you can before they oust you for : poor performance for inside fund shareholders !!! GOFF has brought no value in 3 years this month ! FOUSE NEVER DID !!! she created a NEW HISTORIC LOW $16.95 from $62.10 !!!! ( but she was always a loser from Bunge and discarded from Celgene , but was David Schenkien’s girl,Friday ) The game is the same with these two losers , Kapusta and Goff !!! David Meeker , $RYTM, are you reading this ??? Your RYTM was $3 in 2023, today $98 !!! Guess one knows , WHO is with creating value and WHOM ARE NOT !!!!
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Aug. 21 at 9:53 AM
WATCHLIST AUG 21 2025. $RYTM Rhythm Pharmaceuticals Announces The FDA Has Accepted Its Supplemental New Drug Application For Setmelanotide To Treat Acquired Hypothalamic Obesity $MSW Ming Shing Group Enters Into A Bitcoin Purchase Agreement With Winning Mission Group Limited For The Purchase Of 4,250 Bitcoins $BZ Jefferies Maintains Buy on Kanzhun, Raises Price Target to $24 $CNVS Cineverse And ElementalTV Form Strategic Partnership To Enhance Streaming Reach With Advanced Audience Intelligence And Identity Resolution $LTH Life Time Launches Melatonin-Free Sleep Supplement 'LTH Dream' With Triple Magnesium Blend For Restful, Grogginess-Free Sleep
0 · Reply
abcdzepeda
abcdzepeda Aug. 20 at 8:43 PM
$RYTM it looks like all us rhythmites are going to have an awesome Christmas! Hold onto your hat, folks, because we are in for an awesome ride from now until December.
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 20 at 8:12 PM
$RYTM No FDA-approved therapies currently exist for acquired hypothalamic obesity. First in class!!!!
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 20 at 8:11 PM
$RYTM very bullish ~20% BMI reduction vs placebo in acquired hypothalamic obesity — very strong efficacy in both adults and children.
0 · Reply
BigSqueezeComing
BigSqueezeComing Aug. 20 at 8:10 PM
$RYTM Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity By Rhythm Pharmaceuticals, Inc. | August 20, 2025, 4:01 PM
0 · Reply
justiceforb_85
justiceforb_85 Aug. 19 at 7:11 PM
$RYTM showing incredible strength. Is this a buy-out candidate?
0 · Reply
Quantumup
Quantumup Aug. 19 at 6:35 PM
Baird reiterated $SLNO Outperform-$121 and said, 'Buyers on Pullback Following Short Report.' $AARD $RYTM $ACAD $BIIB $RHHBY Baird additionally said in its note: The Soleno short report, published on Friday, claims Vykat is a ticking safety time bomb and that the PWS physician and patient communities are generally averse to trying Vykat, both of which we think are sensationalized. We live in the age of anecdotal evidence, so we don't want to underestimate the risk of some Facebook posts. However, we think the safety profile over hundreds of patients treated commercially remains consistent with the clinical trial experience, and we expect the impressive early growth to continue.
0 · Reply
GeneralAdam
GeneralAdam Aug. 19 at 11:02 AM
$RYTM I usually trade only small bio stocks, does bigger guys with few bilion market cap still dillute like crazy?
0 · Reply
JHaiko
JHaiko Aug. 19 at 10:39 AM
$BTAI Canaccord’s price will be &7.5-8 per share. Based on previous offerings like $RYTM. Dilution of about 10% which is pretty much ok.. ;)
0 · Reply
JHaiko
JHaiko Aug. 19 at 10:34 AM
Canaccord's price will be $7.5-8. (based on previous offerings like $RYTM. Dilution of about 10% which is pretty much ok.. ;)
0 · Reply
wjmax
wjmax Aug. 18 at 4:08 PM
$IOVA $RYTM is Eldelman's 4th largest holding. It's Baker Brothers' 7th. $RYTM's lead product, Bivamelagon (LB54640), a melanocortin MC 4 receptor agonist, can impact dendritic cells, potentially influencing immune responses and inflammation. Studies suggest that activation of the MC4 receptor can modulate dendritic cell function, impacting their ability to stimulate T cells and potentially altering inflammatory processes. https://rhythmtx.com/clinical-trials/
1 · Reply
Quantumup
Quantumup Aug. 18 at 11:45 AM
H.C. Wainwright⬆️ $SLNO PT to $110 from $100, reit'd Buy and says that >80% of filed Citizen Petitions (equaling many) since 2001 do not result in withdrawals of products from the U.S. markets and believes Scorpions effort will be unsuccessful. $RYTM $AARD $ACAD $BIIB RHHBY H.C. Wainwright additionally said in its note to investors:
1 · Reply
biolover
biolover Aug. 15 at 1:58 AM
$VKTX when I look at other biotechs such as $RYTM with MC $6.5 B On a wt loss shot ( $400 k per year for syndromes obesity ) I agree with below that BL should consider GIA, raise post data and screw the shorts. Let them stay trapped forever.
0 · Reply